Understanding Mesothelioma Classification and Staging: Insights from the IASLC Mesothelioma Staging Project

ByHolly Zink
Understanding Mesothelioma Classification and Staging: Insights from the IASLC Mesothelioma Staging Project

Malignant pleural mesothelioma is a rare, aggressive cancer linked to asbestos. Proper classification and staging are key. They guide treatment and predict outcomes.

The TNM system by the IASLC is crucial. It categorizes cancers based on their size and spread. The IASLC Mesothelioma Staging Project now aims to improve the ‘N’ descriptors for the 9th edition.

A new article discusses mesothelioma staging, focusing on suggested changes for ‘N’ descriptors.

The TNM Classification System

The TNM classification system is a universally accepted standard for staging cancer, including pleural mesothelioma. It categorizes cancer based on three key components:

  • T (Tumor): Refers to the size and extent of the primary tumor.
  • N (Node): Indicates whether the cancer has spread to regional lymph nodes.
  • M (Metastasis): Describes the presence of distant metastatic spread.

Each component is assigned a number to indicate the severity or extent of the disease, which collectively determines the overall stage of the cancer.

Staging of Pleural Mesothelioma

Staging mesothelioma accurately is critical for guiding treatment decisions and predicting patient prognosis. The stages of pleural mesothelioma are:

  • Stage I: Cancer is localized to the pleura on one side of the chest and has not spread to lymph nodes or distant sites.
  • Stage II: Cancer has spread to the pleura on one side and nearby lymph nodes.
  • Stage III: Cancer has spread to the pleura, nearby lymph nodes, and may involve parts of the chest wall or diaphragm.
  • Stage IV: Cancer has metastasized to distant organs or tissues.

Proposals for the ‘N’ Descriptors in the 9th Edition TNM Classification

The IASLC Mesothelioma Staging Project aims to refine the staging system to enhance its accuracy and clinical utility. In their study, the team analyzed 3,598 cases of pleural mesothelioma diagnosed between 2013 and 2022, focusing on the ‘N’ categories (lymph node involvement).

The existing 8th edition N categories (N0, N1, N2) performed adequately in the 9th edition dataset. Patients with no lymph node involvement (N0) had a median overall survival (OS) advantage compared to those with lymph node involvement (N1): 23.2 months vs. 18.5 months.

For patients who underwent surgical resection, those with no lymph node metastases (pN0) had a 3-year OS of 48%, significantly better than those with nodal involvement (pN1).

There was no significant difference in OS between patients with single versus multiple station nodal metastases. The number of nodal stations sampled at the time of resection did not impact OS.

Based on these findings, the study concluded that no changes to the N categories were necessary for the 9th edition of the pleural mesothelioma staging system.

Why Accurate Staging Matters

Accurate staging of mesothelioma is essential for several reasons:

  1. Treatment Planning: Staging helps determine the most appropriate treatment approach, such as surgery, chemotherapy, or radiation therapy.
  2. Prognosis: It provides critical information about the likely course and outcome of the disease.
  3. Clinical Trials: Staging ensures that patients are appropriately selected for clinical trials, which are crucial for developing new treatments.

Staging Project

The IASLC Mesothelioma Staging Project improved the ‘N’ classification for the TNM system’s 9th edition. This work emphasizes accurate staging for pleural mesothelioma. The study found that current N categories are effective. This ensures doctors can accurately stage and plan treatments.

For patients, knowing their mesothelioma stage is crucial for treatment decisions. Updates in staging promise better outcomes and tailored care as research advances.

Source:

Bille, Andrea, R. Taylor Ripley, Dorothy J. Giroux, Ritu R. Gill, Hedy L. Kindler, Anna K. Nowak, Isabelle Opitz, et al. “The IASLC Mesothelioma Staging Project: Proposals for the ‘N’ Descriptors in the Forthcoming 9th Edition of the TNM Classification for Pleural Mesothelioma.” Journal of Thoracic Oncology, May 9, 2024. https://doi.org/10.1016/j.jtho.2024.05.003.

Similar Posts

Mesothelioma Blood Test May Be Possible
|

Mesothelioma Blood Test May Be Possible

ByAlex Strauss

An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma
| |

Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

ByAlex Strauss

Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

Inflammation Both “Friend and Foe” in Mesothelioma
| |

Inflammation Both “Friend and Foe” in Mesothelioma

ByAlex Strauss

An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment
| |

FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

ByAlex Strauss

In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

Mesothelioma Surgeons Report New Biopsy Technique
| |

Mesothelioma Surgeons Report New Biopsy Technique

ByAlex Strauss

A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

New Serum Marker Could Improve Mesothelioma Diagnosis
|

New Serum Marker Could Improve Mesothelioma Diagnosis

ByAlex Strauss

Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…